Please login to order a test.
Oncomine® Dx Target Test-Lung
- NGS FDA
Please provide a copy of the pathology report indicating a diagnosis of NSCLC or related ICD10 code on the requistion. Test will be delayed if the pathology report and clinical indication are not received.
Please direct any questions regarding this test to customer service at 800-345-4363.
Expected Turnaround Time
10 - 14 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
- BRAF Gene Mutation Analysis
- ALK FISH With Reflex to RET and ROS1
- ALK FISH, Non−Small-cell Lung Cancer
- Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis, Non−Small-cell Lung Cancer (Single-base Extension)
- Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis, Non-Small-cell Lung Cancer (Real-time PCR, Version Two Assay)
- ROS1 Oncology FISH
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides from NSCLC
Tumor Size mm2
Resection or Surgical Biopsies
> or =, but <10
9 USS & 1 H&E
> or = 10
2 USS & 1 H&E
Core Needle Biopsies
> or = 1
9 USS & 1 H&E
Tumor surface area greater than or equal to 4mm2 tumor area; tumor content greater or equal to 10%. Resection or Surgical Biopsies: 1 H&E and 2 unstained slides (5 um) Core Needle Biopsies: 1 H&E and 9 unstained slides (5 um)
FFPE block or slides
Indicate date and time of collection on test request form.
Causes for Rejection
Specimens not from NSCLC; tumor block or slides containing no tumor; tumor area <1mm2; tumor content in the region of interest <10%; broken or stained slides; decalcified specimens
The Oncomine® Dx Target Test-Lung is indicated to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling.
List of variants for therapeutic use
L858R, Exon 19 deletions
TAFINLAR® (dabrafenib) in combination with MEKINST® (trametinib)
The test is not indicated to be used for standalone diagnostic purposes, screening, monitoring, risk assessment, or prognosis. Results other than those listed in Table 1 are indicated for use only in patients who have already been considered for all appropriate therapies. Safe and effective use has not been established for selecting therapies using this device for the variants in Table 1 in tissue types other than NSCLC. Analytical performance using NSCLC specimens has been established for the variants listed in Table 2.
List of variants with established
analytical performance only
The Oncomine® Dx Target Test-Lung is a qualitative diagnostic test that uses targeted high-throughput, parallel-sequencing technology to detect single-nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM™ Dx Instrument System.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|581475||Oncomine(R) Dx Target-Lung||230163||Specimen Status||N/A|
|581475||Oncomine(R) Dx Target-Lung||581476||DNA & RNA||N/A|
|581475||Oncomine(R) Dx Target-Lung||581477||Microdissection Performed||N/A|
|581475||Oncomine(R) Dx Target-Lung||581479||DNA only||N/A|